Analyst Ratings for Legend Biotech
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has received positive analyst ratings in the last quarter, with 3 bullish and 2 somewhat bullish ratings. No bearish or indifferent ratings were observed. The average 12-month price target for LEGN, according to 5 analysts, is $88.2, with a high of $93.00 and a low of $85.00. This average price target has increased by 1.09% over the past month.
October 18, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive analyst ratings and an increased price target suggest a bullish outlook for Legend Biotech in the short term.
Analyst ratings are a significant factor influencing stock prices. The positive ratings and increased price target for Legend Biotech indicate analysts' confidence in the company's performance, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100